PLK1 and acute myeloid leukemia: Importantly, our retrospective analysis of a clinical trial evaluating the PLK1 inhibitor onvansertib for the treatment of AML identifies evidence supporting the notion that FANCA deficiency may predict clinical response to PLK1 inhibition.